In this issue of Cancer Cell, Woolston et al. show that colorectal cancers that become refractory to initially effective anti-EGFR therapy contain an abundance of stromal and immune cells, irrespective of the contextual presence of resistance-conferring mutations. This reconfiguration puts forward therapeutic opportunities for patients who relapse on EGFR-targeting treatment.
The Stromal and Immune Landscape of Colorectal Cancer Progression during Anti-EGFR Therapy
Catalano I.;Trusolino L.
Last
2019-01-01
Abstract
In this issue of Cancer Cell, Woolston et al. show that colorectal cancers that become refractory to initially effective anti-EGFR therapy contain an abundance of stromal and immune cells, irrespective of the contextual presence of resistance-conferring mutations. This reconfiguration puts forward therapeutic opportunities for patients who relapse on EGFR-targeting treatment.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Trusolino & Catalano_Preprint.pdf
Accesso aperto
Descrizione: Articolo principale
Tipo di file:
PREPRINT (PRIMA BOZZA)
Dimensione
427.64 kB
Formato
Adobe PDF
|
427.64 kB | Adobe PDF | Visualizza/Apri |
|
Catalano & Trusolino_Cancer Cell_2019_Postprint.pdf
Open Access dal 02/08/2020
Descrizione: Articolo principale
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
428.16 kB
Formato
Adobe PDF
|
428.16 kB | Adobe PDF | Visualizza/Apri |
|
1-s2.0-S1535610819302922-main.pdf
Accesso riservato
Descrizione: Articolo principale
Tipo di file:
PDF EDITORIALE
Dimensione
1.16 MB
Formato
Adobe PDF
|
1.16 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
